65,437 trials
Mild Cognitive Impairment
Primary: Visuospatial Problem Solving Battery (VSP) — .30; .29; .097; .52 Mean Difference Score (VPS Total Score)
Chronic Low-back Pain
Primary: Change From Baseline for Average Pain Intensity as Measured by the NRS — -1.57; -2.09 score on a scale
Hernia · Hernia, Diaphragmatic · Hernia, DIaphragmatic, Congenital
Primary: Proportion of Neonate Survival at Discharge From Hospital — 1; 3 Participants
Social Anxiety
Primary: Liebowitz Social Anxiety Scale — 81.05; 82.74; 64.11; 73.05 score on a scale
Diabetic Macular Edema
Primary: Incidence of Treatment-Emergent Adverse Events (Safety and Tolerability) — 3; 2; 1; 59 Participants
Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma · Lung Cancer
Primary: Percentage of Lymph Nodes With Adequate Samples — 79; 78.5 Percentage of Lymph Nodes
Recurrent Lung Non-Small Cell Carcinoma · Stage IV Lung Non-Small Cell Cancer AJCC v7
Primary: Number of Participants With at Least One Dose Limiting Toxicity (DLT) — 2; 0 participants
Acute Myeloid Leukemia
Primary: Overall Survival — 5.9; 5.7 Months — p=<0.0249
Iron Deficiency Anemia
Primary: Change in Hemoglobin g/dL — 2.22; 1.92 g/dL — p=0.3108
Meniere's Disease · Ménière's Vertigo · Vertigo, Intermittent
Primary: Change in Ménière's Vertigo Attack Frequency Between Lamotrigine and Placebo Group — 18.88; 18.00; 13.50; 4.57 Average Total Number of Vertigo Attacks — p=0.5618
Evaporative Dry Eye
Primary: Tear Evaporation Rate — 1.15; 1.38; 1.26; 1.32 % relative humidity per second — p=0.002
Oncology · MET Gene Amplification · NSCLC
Primary: Part 1: Occurrence of DLTs During Cycle 1 of Sym015 Administration — 0; 0; 0; 0 Number of DLTs
Ventral Hernia
Primary: Pain Scores — 30.7; 30.7 T-Score
Non-Hodgkin's Lymphoma
Primary: 2-year PFS From the Start of Induction Therapy Conditional — 86.6; 90.6; 0.4 percentage of patients
Visual Acuity
Primary: Visual Performance (logMAR) — -0.08; -0.06; -0.01; 0.00 logMAR